Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Idarubincin and Amufostine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Idarubicin plus amifostine |
| 2 | EXPERIMENTAL | Idarubincin |
| Name | Type | Description |
|---|---|---|
| Idarubincin and Amufostine (Ethyol) | DRUG | Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36) |
| Idarubincin | DRUG | Idarubincin (12mg/m2) and ara-C(N-18) |
Inclusion Criteria: * Adult men and women of at least 60 years of age at the time of entry or randomization; * Histologically proven AML with at least 20% myeloblasts based on bone marrow aspiration and biopsy performed within 5 days prior to entry or randomization; History of prior MDS allowed pro...
Top 20 of 60 competitors
Idarubincin and amufostine is an investigational combination being studied in leukemia, specifically acute myeloid leukemia. It pairs idarubicin, a small molecule chemotherapy agent, with amifostine, also known as Ethyol. The combination was evaluated in older patients with acute myeloid leukemia, a blood cancer affecting the bone marrow.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of the idarubincin and amufostine combination. The company sponsored the clinical research evaluating this regimen in leukemia. AstraZeneca is a global pharmaceutical company with an oncology portfolio that includes both chemotherapy and supportive care agents.
Idarubincin and amufostine is in Phase 1 clinical development. The single registered trial of this combination was a Phase 1 study, and it has been completed. The drug combination is investigational and has not been approved by the FDA for any indication.
Idarubincin and amufostine has been studied in one clinical trial, NCT00086099, titled a study evaluating the addition of amifostine (Ethyol) to idarubicin and cytosine arabinoside in older patients with acute myeloid leukemia. The Phase 1 trial enrolled 54 patients, was controlled and randomized, and was conducted in the United States and Israel.
Amufostine is also known as amifostine, sold under the brand name Ethyol. Idarubincin and amufostine is the combination of idarubicin with amifostine, so Ethyol refers to only one component of the regimen, not the combination itself. Searches for idarubincin and amufostine (Ethyol) refer to this same drug combination.
The completed Phase 1 trial NCT00086099 evaluated adding amifostine, also called Ethyol, to idarubicin and cytosine arabinoside in older patients with acute myeloid leukemia. It enrolled 54 patients aged 60 years and older, included both sexes, and was a controlled, randomized study conducted in the United States and Israel.